Pharmaceuticals, Biotechnology and Life Sciences
The EUCAIM consortium and the European Commission have the first public release of its platform, Cancer Image Europe, marking a major milestone in the project’s development and an exciting step towards achieving its vision and goals.
Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update provided within its Interim Results on 14 September.
Poolbeg Pharma, a clinical-stage biopharmaceutical company, said last week that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled.
A commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, Basilea Pharmaceutica, said…
Futura Medical, a UK pharmaceutical company developing innovative sexual health products, has been granted allowance of its EU patent which…
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022 sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.
Hemogenyx Pharmaceuticals, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, committed to progressing HEMO CAR-T to clinical trials as the its next step.
The US Food and Drug Administration (FDA) has granted Germany based 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL), the company said in a press release on Wednesday.
The life science group Sartorius and a UK-based startup SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for biopharmaceutical drugs.
Regeneron Pharmaceuticals and Sanofi have received U.S. Food and Drug Administration (FDA) acceptance for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).